Featured
Vital Signs: Future of Healthcare
Produced by Onyx, Published in Fortune
Is a world without eyedrops possible?
SpyGlass Pharma is poised to revolutionize glaucoma treatment by implanting an innovative long-term drug delivery system directly inside the eye. Their treatment promises to continuously release eyedrop medication for 3 years after surgery, as opposed to using eye drops manually every day.
Blood tests for cancer are here and Guardant Health is leading the charge
Guardant Health has seen a string of consistent firsts - most recently FDA approval for colorectal cancer in July, 2024
GERD affects millions of Americans. This drug is the first major innovation in three decades.
GERD affects 65 million Americans, yet innovation in treatment had stagnated. Phathom Pharmaceuticals' FDA approval of VOQUEZNA® (vonoprazan) is a big moment for patients.
Let there Belite: an oral pill for vision loss
If left untreated, Stargardt disease and Geographic Atrophy almost always lead to vision loss and blindness - but a groundbreaking oral treatment in the last stage of clinical trials offers new hope.
What are GLP-1 agonists and how valuable are they?
GLP-1 is quickly becoming one of the most famous hormones in the world.
Under The Microscope: The Basics of Cell and Gene Therapy
Genomics is seeing its golden age in the clinic. How did we get here?
Wearable diagnostics: Continuous Glucose Monitoring Devices
How do they work, and how big is the market?
Announcing Vital Signs in Fortune
We will publish our in-depth healthcare report, Vital Signs, in Fortune magazine on December 1, 2024. Vital Signs: Future of Healthcare will appear in Fortune ahead of one of the most important events in the industry: JPM Week, the annual healthcare conference hosted by J.P. Morgan at the Westin
Top Satellite Events at JPM Week
The must-read guide to one of the most anticipated periods of the year for professionals in biotech, pharma, and life sciences.
The 3 Biggest Biotech Events in 2025
We expect the attendance for each to be well over 20,000 in 2025.